SCHEMBL5151018

SCHEMBL5151018

CCCN(CCC)c1cc2c(cc1C(C)N(Cc1cccc(C#N)c1)C(=O)O)CCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.39
SLC6A4 P31645 2/20 0.39
SLC6A3 Q01959 2/20 0.39
NLRP3 Q96P20 1/20 0.38
MEP1A Q16819 1/20 0.38
MEP1B Q16820 1/20 0.38
NR3C1 P04150 1/20 0.38
PTGES O14684 6/20 0.37
DCUN1D1 Q96GG9 1/20 0.36
KCNN4 O15554 1/20 0.36
KCNA5 P22460 1/20 0.36
FOLH1 Q04609 1/20 0.36
FFAR1 O14842 1/20 0.36
GLA P06280 1/20 0.35
MAOB P27338 2/20 0.35
MAOA P21397 1/20 0.35
RORC P51449 1/20 0.35
MEN1 O00255 1/20 0.35
USP2 O75604 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5148377 0.85 RIPK1 (0.39) NR3C1PTGESDCUN1D1RORC
SCHEMBL5669028 0.82 PTGES (0.39) SLC6A2SLC6A4SLC6A3NLRP3MEP1A
SCHEMBL5150322 0.77 TACR1 (0.40) PTGESDCUN1D1
SCHEMBL5148332 0.77 SERPINE1 (0.37) DCUN1D1
SCHEMBL1899466 0.76 NLRP3 (0.41) NLRP3MEP1AMEP1BNR3C1PTGES
SCHEMBL5672380 0.74 MAOA (0.38) SLC6A2SLC6A4SLC6A3NLRP3NR3C1
SCHEMBL5148370 0.74 PSEN1 (0.36) DCUN1D1
SCHEMBL1906692 0.73 UBE2M (0.34) DCUN1D1FFAR1
SCHEMBL5148327 0.73 SERPINE1 (0.36) DCUN1D1
SCHEMBL2262702 0.73 CHRM5 (0.35) PTGESDCUN1D1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070054839-A1 Method of inhibiting remnant lipoprotein production JAPAN TOBACCO INC. (JP) 2007-03-08 US claimed
US-20060270705-A1 Method for inhibiting lipid absorption and lipid absorption inhibitor JAPAN TOBACCO INC. (JP) 2006-11-30 US claimed
US-20070054839-A1 Method of inhibiting remnant lipoprotein production JAPAN TOBACCO INC. (JP) 2007-03-08 US disclosed
US-20060270705-A1 Method for inhibiting lipid absorption and lipid absorption inhibitor JAPAN TOBACCO INC. (JP) 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054839-A1 Method of inhibiting remnant lipoprotein production CETP, PCSK9, LIPA SLC6A2 3645/4885SLC6A4 4124/4885SLC6A3 4717/4885
US-20060270705-A1 Method for inhibiting lipid absorption and lipid absorption inhibitor CETP, SI, LIPC SLC6A2 619/4885SLC6A4 527/4885SLC6A3 1859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.